Last updated: July 17, 2026

Application No. 18/541,584

COMBINATION COMPRISING A NEUROTENSIN RECEPTOR BINDING COMPOUND AND FOLFIRINOX

Non-Final OA

Filed

Dec 15, 2023

Priority

Jun 16, 2021 — provisional 63/211,312 +1 more

Examiner

BAEK, JONGHWAN NMN

Art Unit

1618

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Fusion Pharmaceuticals Inc.

OA Round

1 (Non-Final)

Interview Optional

— +0.0% interview lift. Interview lift (+0.0%) is below the 15.0% threshold. A written response is recommended.

Based on 4 resolved cases, 2023–2026

Examiner Intelligence

BAEK, JONGHWAN NMN View full profile →

Grants 75% — above average

Career Allowance Rate

3 granted / 4 resolved

+15.0% vs TC avg

Minimal +0% lift

Without

With

+0.0%

Interview Lift

resolved cases with interview

Typical timeline

2y 7m

Avg Prosecution

48 currently pending

Career history

Total Applications

across all art units

Statute-Specific Performance

§103

58.7%

+18.7% vs TC avg

§102

3.3%

-36.7% vs TC avg

§112

5.4%

-34.6% vs TC avg

Black line = Tech Center average estimate • Based on career data from 4 resolved cases

Prosecution Timeline

Dec 15, 2023

Application Filed

Jun 05, 2026

Non-Final Rejection mailed (current)

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

75%

Grant Probability

75%

With Interview (+0.0%)

2y 7m (~0m remaining)

Median Time to Grant

Low

PTA Risk

Based on 4 resolved cases by this examiner. Grant probability derived from career allowance rate.